# Mounjaro Resource Links - Quick Reference

This document contains all the links to downloadable/accessible Mounjaro resources.
Please download these manually from the URLs provided.

---

## Official FDA Documents

| Document | URL |
|----------|-----|
| FDA Prescribing Information (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s013lbl.pdf |
| FDA Approval Letter | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215866Orig1s000ltr.pdf |
| FDA Review Documents | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000TOC.cfm |

---

## Clinical Trial Publications

### SURMOUNT Program (Weight Loss)

| Trial | Journal | URL |
|-------|---------|-----|
| SURMOUNT-1 | NEJM | https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 |
| SURMOUNT-1 | PubMed | https://pubmed.ncbi.nlm.nih.gov/35658024/ |
| SURMOUNT-2 | NEJM | https://www.nejm.org/doi/full/10.1056/NEJMoa2303162 |
| SURMOUNT-4 | NEJM | https://www.nejm.org/doi/full/10.1056/NEJMoa2312774 |

### SURPASS Program (Type 2 Diabetes)

| Trial | Resource | URL |
|-------|----------|-----|
| SURPASS Overview | Eli Lilly | https://www.lilly.com/news/stories/surpass-clinical-program |
| SURPASS-2 | PubMed | https://pubmed.ncbi.nlm.nih.gov/34170647/ |
| SURPASS-PEDS | The Lancet | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00834-6/fulltext |

### ClinicalTrials.gov

| Trial | ID | URL |
|-------|-----|-----|
| SURMOUNT-1 | NCT04184622 | https://clinicaltrials.gov/study/NCT04184622 |
| SURMOUNT-2 | NCT04657003 | https://clinicaltrials.gov/study/NCT04657003 |
| SURPASS-CVOT | NCT04255433 | https://clinicaltrials.gov/study/NCT04255433 |

---

## Eli Lilly Official Resources

| Resource | URL |
|----------|-----|
| Mounjaro Patient Site | https://www.mounjaro.com |
| Mounjaro HCP Portal | https://hcp.mounjaro.lilly.com |
| Getting Started Guide | https://www.mounjaro.lilly.com/hcp/getting-started |
| Dosing Information | https://www.mounjaro.lilly.com/hcp/dosing |
| Savings & Support | https://www.mounjaro.lilly.com/savings |
| Lilly Medical | https://www.lillymedical.com |

---

## Research & Market Data

| Resource | URL |
|----------|-----|
| GLP-1 Patient Demographics | https://www.realchemistry.com/insights |
| Obesity Treatment Guidelines | https://www.obesitymedicine.org/resources |
| ADA Standards of Care | https://professional.diabetes.org/standards-of-care |

---

## Patient Education Materials

| Resource | URL |
|----------|-----|
| Diabetes UK - Mounjaro | https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/taking-mounjaro |
| Cleveland Clinic - GLP-1 | https://my.clevelandclinic.org/health/drugs/24165-glp-1-agonists |
| Mayo Clinic | https://www.mayoclinic.org/drugs-supplements/tirzepatide-injection-route-subcutaneous/description/drg-20529178 |

---

## Safety Information

| Resource | URL |
|----------|-----|
| FDA Drug Safety | https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers |
| MedWatch | https://www.fda.gov/medwatch |
| Drugs.com Mounjaro | https://www.drugs.com/mounjaro.html |

---

## Note on Brand Assets

Eli Lilly does **NOT** publicly release:
- Brand guidelines
- Logo files
- Marketing templates
- Creative assets

These require:
1. Partnership with Eli Lilly
2. HCP credentialing for specific portals
3. Agency relationships

For brand assets, contact: https://www.lilly.com/contact-us
